Linking SOX10 to a slow-growth resistance phenotype
Slow-cycling BRAFV600E melanoma cells are notoriously resistant to standard chemotherapy or targeted therapy but the underlying mechanism remains elusive.Now a new study unlocks this mystery and offers novel insights into developing more effective therapeutic interventions.Molecular-guided targeted therapies have been effective in shrinking the bulk of BRAFV600E tumors,particularly in patients with advanced or unresectable melanoma ”1”.Unfortunately,therapeutic response is not durable,which is inevitably followed by tumor relapse.
24
2014-09-10(万方平台首次上网日期,不代表论文的发表时间)
906-907